articleTop 10% cited

TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study

European Journal of Endocrinology · 2007 · Vol. 158(1) · pp. 69–75

Peter Laurberg✉(Aarhus University Hospital)Göran Wallin(Karolinska University Hospital)Leif Tallstedt(Karolinska Institutet)Mirna Abraham‐Nordling(Karolinska University Hospital)G. E. F. Lundell(Sophiahemmet Hospital)Ove Törring(Stockholm South General Hospital)

View via DOI Publisher page

Abstract

The majority of patients with Graves' disease gradually enter remission of TSH-receptor autoimmunity during medical or after surgical therapy, with no difference between the types of therapy. Remission of TSH-receptor autoimmunity after radioiodine therapy is less common.

Thyroid Disorders and Treatments Ophthalmology and Eye Disorders Growth Hormone and Insulin-like Growth FactorsTrabMedicineGraves' diseaseAutoimmunityEuthyroidInternal medicineThyroidEndocrinologyGastroenterologyDisease

MeSH terms

AdultAutoantibodiesGraves DiseaseHumansIodine RadioisotopesMiddle AgedProspective StudiesReceptors, ThyrotropinAntithyroid AgentsThyroidectomyThyroxineTime FactorsTriiodothyronineAutoimmunityTreatment Outcome

Citations

428

FWCI

6.05

field-weighted impact

References

Percentile

97%

vs. same field & year

Citations per year

Cited by

The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy

European Journal of Endocrinology · 2021 · 912 citations

References

Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy

Clinical Endocrinology · 2000 · 321 citations

Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.